Lung carcinoma with EGFR mutation
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Lung carcinoma with EGFR mutation is a molecular subtype of lung carcinoma. Morphologically, these tumours are typically adenocarcinomas.
General
- Testing indicated in non-small cell carcinoma, adenosquamous carcinoma of the lung, as well as lung adenocarcinoma.
- Testing done together with ALK.
- EGRF mutation excludes ALK rearrangement.[1]
Treatement:[2]
Associations
Varies significantly by population:[3]
| Population | Prevalence | Category |
|---|---|---|
| Europe | 14% | Geographic |
| China | 38% | Geographic |
| Females | 44% | Patient characteristics |
| Males | 24% | Patient characteristics |
| Non-smokers | 49% | Patient characteristics |
| Smokers or past smokers | 22% | Patient characteristics |
| Adenocarcinoma | 38% | Pathology |
| Non-adenocarcinoma | 12% | Pathology |
Sign out
Lung core biopsy, left lower lobe: - EGFR mutation POSITIVE, ALK rearrangement NEGATIVE
See also
- Lung carcinoma with ALK rearrangement.
- Epidermal growth factor receptor inhibitors.
- ROS1-rearranged non-small cell lung carcinoma.
References
- ↑ Gainor, JF.; Varghese, AM.; Ou, SH.; Kabraji, S.; Awad, MM.; Katayama, R.; Pawlak, A.; Mino-Kenudson, M. et al. (Aug 2013). "ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.". Clin Cancer Res 19 (15): 4273-81. doi:10.1158/1078-0432.CCR-13-0318. PMID 23729361.
- ↑ da Cunha Santos, G.; Shepherd, FA.; Tsao, MS. (2011). "EGFR mutations and lung cancer.". Annu Rev Pathol 6: 49-69. doi:10.1146/annurev-pathol-011110-130206. PMID 20887192.
- ↑ Zhang, YL.; Yuan, JQ.; Wang, KF.; Fu, XH.; Han, XR.; Threapleton, D.; Yang, ZY.; Mao, C. et al. (Nov 2016). "The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.". Oncotarget 7 (48): 78985-78993. doi:10.18632/oncotarget.12587. PMID 27738317.